RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 45-55
  • Taxpayers' Costs For Unregulated Drug Prescriptions Explode By 3,000% In Three Years

    Taxpayers' Costs For Unregulated Drug Prescriptions Explode By 3,000% In Three Years
    Unregulated drugs produced by controversial compounding pharmacies are costing Connecticut taxpayers up to $24 million this year in prescription payments on behalf of state employees and retirees, a stunning 3,000 percent increase from their $800,000...
  • Abbott first quarter earnings boosted to $2.29B by divestitures

    Abbott first quarter earnings boosted to $2.29B by divestitures
    Health care products and pharmaceuticals company Abbott Laboratories reported first-quarter 2015 results Wednesday marked by two big sales that boosted earnings while beating sales growth. A snapshot of the quarter, and a bit on what's to come: By the...
  • Big pharma should support the NIH

    Big pharma should support the NIH
    Recently at a reception, one of my faculty colleagues at Johns Hopkins expressed concern about her academic future. The pay line for National Institutes of Health (NIH) grants in her field was 7 percent; that means that she has to spend two or three weeks...
  • FDA approves Amgen heart failure drug Corlanor

    FDA approves Amgen heart failure drug Corlanor
    Biotech company Amgen Inc. took a key step in its expansion into cardiovascular drugs Wednesday when the Food and Drug Administration approved its heart failure drug for sale in the United States. The drug called ivabradine is an oral medication that...
  • Antidepressants: a deadly treatment?

    Antidepressants: a deadly treatment?
    The crash of Germanwings Flight 9525, allegedly the intentional act of co-pilot Andreas Lubitz, and the deaths of all 150 people on board is indeed a tragedy. But some good may come out of it if it induces people to take another look at those substances...
  • FDA approves first lower-cost biotech drug

    FDA approves first lower-cost biotech drug
    Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients. Biotech drugs are powerful, injected...
  • AbbVie to buy leukemia drug maker Pharmacyclics for $21 billion

    AbbVie will spend about $21 billion to buy fellow drugmaker Pharmacyclics and add another major revenue producer to a portfolio that already includes the world's top-selling drug. The deal will give the North Chicago, Ill., drugmaker Imbruvica, a blood...
  • Baltimore biotech lands FDA approval of drug for rare digestive illness

    Baltimore biotech lands FDA approval of drug for rare digestive illness
    The Food and Drug Administration on Tuesday approved Cholbam, developed by Baltimore biotechnology company Asklepion Pharmaceuticals, for treatment of a rare disease that prevents people from making key digestive acids. The approval means Retrophin, a...
  • Allergan sale to Actavis complete; CEO David Pyott is leaving

    Allergan sale to Actavis complete; CEO David Pyott is leaving
    The $70-billion purchase of Botox maker Allergan Inc. of Irvine by Irish company Actavis has closed, Actavis confirmed Tuesday. Allergan’s longtime leader, David E.I. Pyott, will not have a position in the new company, which will be called...
  • AbbVie wins 3-company battle to buy cancer drugmaker for $21B

    AbbVie wins 3-company battle to buy cancer drugmaker for $21B
    Three bidders remained at the last hour, but North Chicago-based AbbVie walked away the winner late Wednesday to buy a California company and its expected blockbuster blood cancer drug. "I've been through a lot of these, and I'd say this was probably one...
  • FDA: Hospira's corrective actions at Italy plant weren't enough

     FDA: Hospira's corrective actions at Italy plant weren't enough
    The Food and Drug Administration has warned Hospira that corrective actions the drugmaker made at an Italy facility weren't sufficient, the company disclosed Tuesday in a regulatory filing. The FDA in a March 31 letter said Hospira lacked written...